Low ‐dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: A 5‐y prospective cohort study

In this study, 406 patients on regular HD were involved during a 5‐y follow‐up. Among these, 152 and 254 propensity‐matched patients were enrolled in the aspirin and nonaspirin cohort, respectively. The cumulative survival rate was not significantly higher in the aspirin than in the nonaspirin users (log rank χ2 = 1.080, P = 0.299). Aspirin use was not significantly associated with reduced all‐cause mortality, fatal and nonfatal congestive heart failure, as well as acute myocardial infarction and ischemic stroke. The risk of fatal cerebral hemorrhage was not significantly increased in the aspirin users (HR = 1.795, 95% CI 0.666–4.841, P = 0.174). After adjustment for other confounders, aspirin use was also not associated with decreased risk of all‐cause mortality and CVD. Discussion The present prospective cohort study suggests that low‐dose aspirin use is not associated with a significant decrease in the risks of all‐cause mortality, CVD, and stroke in population undergoing HD (ClinicalTrials.gov number, NCT02261025).
Source: Hemodialysis International - Category: Hematology Authors: Tags: Original Article Source Type: research